Navigation Links
Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy
Date:9/10/2013

WHIPPANY, N.J., Sept. 10, 2013 /PRNewswire/ -- Bayer HealthCare has entered into a strategic alliance with the Broad Institute in Cambridge, Massachusetts in the area of oncogenomics and drug discovery. The Broad Institute, one of the world's most renowned non-profit biomedical research institutes, brings together scientists from Harvard, MIT and the Harvard-affiliated hospitals, and has deep expertise in genomics, cancer, chemical biology, and drug discovery, as well as other areas. The goal of this collaboration is to jointly discover and develop therapeutic agents that selectively target cancer genome alterations over a period of five years. 

"We are excited to collaborate with such a prestigious research institute as the Broad Institute which brings together researchers from Harvard, MIT, and the Harvard hospitals," said Professor Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare. "The Broad Institute's scientists have created impressive systematic catalogues of mutational changes across different types of tumors, laying a foundation for the development of new cancer therapies and diagnostics. The alliance is another significant step underlining our engagement in the field of oncology and personalized medicine."

Oncogenomics is a promising field of oncology research that identifies and characterizes genes which are associated with cancer. Cancer is caused by accumulation of DNA mutations which leads to uncontrolled cell proliferation and tumor formation. The goal of oncogenomics research is to identify new genes which in a modified (mutated) version stimulate (oncogenes) or lose their ability to suppress (tumor suppressor genes) tumor cell growth. This may provide new insights into cancer diagnosis, predicting clinical outcome of cancers, and new targets for cancer therapies. Targeting individual patien
'/>"/>

SOURCE Bayer HealthCare
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
2. FDA Advisory Committee Unanimously Recommends Approval Of Bayers Riociguat In Two Pulmonary Hypertension Indications
3. Statement: Bayer Mourns Passing of Senator Frank Lautenberg
4. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
5. Bayer Employee Named Rising Star by Healthcare Businesswomens Association
6. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
9. U.S. FDA Grants Priority Review to Bayers Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Bayer Consumer Care Voluntarily Recalls 56 Lots of BRONKAID Caplets Dual Action Formula due to Product Labeling Error
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... WASHINGTON , July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. ...
(Date:7/29/2014)... July 29, 2014 Numotion,s Board of Directors has ... will be the company,s new Chief Executive Officer. ... career at GE where he worked primarily for GE Healthcare ... to over $5 billion. His most recent position was as ... "I am thrilled to join Numotion," said Mike ...
Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2
... 3, 2011 Nonin Medical, Inc., the inventor of ... a leader in noninvasive physiological monitoring, announced the worldwide ... Pulse Oximeter for medical monitoring manufacturers. ... wired pulse oximeter will provide a new level of ...
... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) ... Senior Vice President of Research and Development, Cynthia Schwalm ... M.D., as Senior Vice President of Pharmacovigilance. These newly ... the Company prepares for the potential launch of its ...
Cached Medicine Technology:Nonin Medical Launches Low Power Xpod®, Model 3012LP, OEM Pulse Oximeter Globally 2Optimer Pharmaceuticals Expands Senior Management Team 2Optimer Pharmaceuticals Expands Senior Management Team 3Optimer Pharmaceuticals Expands Senior Management Team 4Optimer Pharmaceuticals Expands Senior Management Team 5
(Date:7/30/2014)... The Diabetes Daily Grind had its beginnings ... Ryan Fightmaster hope to gain attention for the website ... 26th of this year, Clour and Fightmaster started this ... diabetic life. By sharing stories on their lessons ... other diabetics will find ways to live with their ...
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review recently ... people how to cure their nasal polyps permanently ... horrible truth about conventional treatments for nasal polyps. , ... will learn how to prevent symptoms related to nasal ... Nasal Polyps Treatment Miracle, as it is reviewed now by ...
(Date:7/30/2014)... The San Diego personal injury lawyers of The ... they are now offering free case reviews for individuals that ... , “Symptoms of asbestos exposure can take years to develop, ... years ago may just now be suffering from the ill ... Melinda J. Helbock A.P.C. “We want people to know that ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nuanced Media, a ... announce the release of the Medical Web Design Trends of ... of research done across multiple agencies and the medical web ... are constantly changing as the industry grows. Therefore it is ... of ideas that consumers enjoy most. New trends are defined ...
(Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
Breaking Medicine News(10 mins):Health News:Strangers Come Together to Form Diabetes Website: Real Messages of Hope and Inspiration 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
... of the disease among those vaccinated were no higher ... (HealthDay News) -- Rates of a rare neurodegenerative disease, ... last year were no higher than among the general ... syndrome were noted after widespread swine flu vaccination in ...
... April 13, 2010 Allergies have become a widespread ... are all increasingly prevalent. The reason? Excessive cleanliness is ... at the Universit de Montral Faculty of Medicine. ... pollution, processed foods, stress, tobacco use, etc. Yet our ...
... 2010) The human mouth is home to an estimated ... moist environment, along with hard tooth surfaces and soft tissues, ... of these bacteria are harmful and can form a film ... eventually more severe kinds of gum disease. Toothpaste ...
... ... features and prices of March special SEO offers, SEO-Peace.com management is pleased to extend its ... features to the client base. , ... Gurgaon, India (PRWEB) April 13, 2010 -- With SEO industry getting more and more ...
... , ... 1 out of every 6 men in the United States (1 in 3 in the ... against prostate cancer by registering for Little Red Door,s Unite 2 Fight Race Against Prostate ... Indianapolis, IN (PRWEB) ...
... with Williams syndrome have no social fear and appear ... 13 (HealthDay News) -- Children with a rare ... and with it, racial prejudice, a new study shows. ... the root cause of racial stereotyping. , French and ...
Cached Medicine News:Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 2Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 3Health News:Why are allergies increasing? 2Health News:Give dirty mouths a brush 2Health News:SEO-Peace.com Extends The March Special SEO Special Offers And Revise Many Services 2Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Kids With Rare Condition Lack Racial Prejudice 2
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: